We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen shares have lagged the market lately, as have those of other drug makers, primarily reflecting political risks related to drug pricing issues. This macro cloud notwithstanding, the analyst likes the large number of blockbuster drugs in Amgen’s portfolio which bodes well for its future growth. Moreover, contribution from new products should be meaningful this year. Additionally, Amgen’s restructuring plan should make it leaner and more cost-efficient. (You can read the full research report on Amgen here>>)
Zacks # 2 (Buy) rated Broadcom shares have been strong performers this year (up more than 20% year-to-date) on greater appreciation for the chipmaker's robust organic growth outlook. The analyst likes the synergistic benefits gained from the merger with Avago. Such gains are likely to increase future profitability through economies of scale and mutual sharing of manufacturing expertise and R&D costs. Additionally, Broadcom maintains an efficient global supply chain with a variable, low-cost operating model. (You can read the full research report on Broadcom here>>)
HSBC Holdings is one of the largest European banks, but it's primarily an Asian operator, with a majority of its recent earnings coming from that region. European banks have been laggards lately and HSBC is no different, though it has been doing better lately on the back of better execution of its restructuring plan that essentially involves reducing the bank's footprint in some regions in order to focus more on its core Asian franchise. The recent sale of its Brazilian operations and using the sale procedes for share buybacks are part of that strategy. Management's committment to maintain and raise the dividend (currently yielding a juicy 5.5%) and cost saving initiatives are some of the positives in the HSBC story. (You can read the full research report on HSBC here>>)
You can find all of today's stock research reports here >>
Free Access: All Zacks Research Reports Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Sheraz Mian
Director of Research
If you want an email notification each time Sheraz publishes a new article, pleaseclick here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for September 2, 2016
Friday, September 2, 2016
Today's must-read reports are for Amgen (AMGN - Free Report) , HSBC (HSBC - Free Report) and Broadcom (AVGO - Free Report) .
Amgen shares have lagged the market lately, as have those of other drug makers, primarily reflecting political risks related to drug pricing issues. This macro cloud notwithstanding, the analyst likes the large number of blockbuster drugs in Amgen’s portfolio which bodes well for its future growth. Moreover, contribution from new products should be meaningful this year. Additionally, Amgen’s restructuring plan should make it leaner and more cost-efficient. (You can read the full research report on Amgen here>>)
Zacks # 2 (Buy) rated Broadcom shares have been strong performers this year (up more than 20% year-to-date) on greater appreciation for the chipmaker's robust organic growth outlook. The analyst likes the synergistic benefits gained from the merger with Avago. Such gains are likely to increase future profitability through economies of scale and mutual sharing of manufacturing expertise and R&D costs. Additionally, Broadcom maintains an efficient global supply chain with a variable, low-cost operating model. (You can read the full research report on Broadcom here>>)
HSBC Holdings is one of the largest European banks, but it's primarily an Asian operator, with a majority of its recent earnings coming from that region. European banks have been laggards lately and HSBC is no different, though it has been doing better lately on the back of better execution of its restructuring plan that essentially involves reducing the bank's footprint in some regions in order to focus more on its core Asian franchise. The recent sale of its Brazilian operations and using the sale procedes for share buybacks are part of that strategy. Management's committment to maintain and raise the dividend (currently yielding a juicy 5.5%) and cost saving initiatives are some of the positives in the HSBC story. (You can read the full research report on HSBC here>>)
Other noteworthy reports we are featuring today include NVIDIA (NVDA - Free Report) , Infosys (INFY - Free Report) , and Campbell Soup (CPB - Free Report) .
You can find all of today's stock research reports here >>
Free Access: All Zacks Research Reports
Starting today, you are invited to download in-depth analysis reports covering more than 1,000 of the most widely followed stocks. Valued at $25 each, they are yours to consult over the next 30 days absolutely free. They feature sensitive Zacks Rank information on each stock that you won't find anywhere else. See the reports free >>
Sheraz Mian
Director of Research
If you want an email notification each time Sheraz publishes a new article, please click here >>